GLP Pathology Services | Charles River Pathology Associates

immunohistochemistry & tissue cross-reactivity 

Immunohistochemistry techniques permit the visualization and morphometric analysis in histological sections of cells. These cells either have their own specific activities or contain particular chemical entities that exploit the ability of antigenic cell components to bind to highly specific antibodies labeled with visible markers for microscopic examination. Charles River Pathology Associates has extensive experience working with these procedures, as well as with a broad range of tissue-based validated methods. In addition, we can develop new procedures to assist you in answering specific questions relating to the activity of your test materials. Interpretation of specimens can be performed subjectively by a pathologist, or advanced quantifiable morphometric techniques can be applied.

Our immunopathology group currently performs preclinical safety assessment for approximately 50-60 humanized, chimeric or murine monoclonal antibodies yearly. We have worked with unconjugated antibodies, antibodies conjugated to a variety of substances and Fab fragments. We have developed techniques to reduce or eliminate the binding of secondary reagents to endogenous immunoglobulin. These techniques allow efficient and specific detection of bound unconjugated IgGs, particularly IgG1, even when the tissue is of the same species as the immunoglobulin.

Services

Charles River scientists also have used immunohistochemical detection of microbial antigens as a tool to elucidate the pathogenesis of infection with retroviruses, paramyxoviruses, filoviruses, flaviviruses, phleboviruses, coronaviruses and rickettsiae.

Charles River was the first contract organization to offer a formal research program designed to characterize cellular and biological responses to external and internal stimuli. Despite the tremendous variety of signals that cells may encounter, the repertoire of responses is limited; cells are either programmed to die, to proliferate or to differentiate. These cellular responses may be exploited for targeted therapeutic strategies since the biological consequences of inappropriate cell death, cell proliferation or alteration include a wide variety of human diseases, such as cancer, autoimmune disorders and CNS disorders.

For additional information about our Immunohistochemistry and Tissue Cross-Reactivity capabilities, please contact us at 1.877.CRIVER.1 or askcharlesriver@crl.com.

Discover the full range of Charles River Products and Services
The Source

For more information, contact us at:

1.877.CRIVER.1 (1.877.274.8371)
askcharlesriver@crl.com

view all

News & Events

view all
May 14 - New Models for Evaluating COPD or ...
May 11 - Expert Safety Testing to Accelerat...
Jun 17-Jun 20 -  Noordwijk aan Zee, the Netherlands - 19th MDO Meeting / 12th European ...
Jun 02-Jun 05 - Vancouver, British Columbia - CALAS
Jun 05-Jun 05 - King of Prussia, Pennsylvania - Assessment of Immunomodulation for Biol...
Jun 05-Jun 08 - Saint Germain sur l’Arbresle, France - Charles River LAL Seminar Series
view all
Scientist I Wilmington, MA
Manager International Tax Wilmington, MA

Charles River Laboratories, Inc.